睾丸癌

Lorch A, Kleinhans A, Kramar A, et al. Sequential versus single high-dose chemotherapy in patients with relapsed or refractory germ cell tumors: long-term results of a prospective randomized trial. J Clin Oncol. 2012;30:800-805.

• 摘要

Albers P, Siener R, Krege S, et al; German Testicular Cancer Study Group. Randomized phase III trial comparing retroperitoneal lymph node dissection with one course of bleomycin and etoposide plus cisplatin chemotherapy in the adjuvant treatment of clinical stage I nonseminomatous testicular germ cell tumors: AUO trial AH 01/94 by the German Testicular Cancer Study Group. J Clin Oncol. 2008;26:2966-2972.

• 全文
• 摘要

1.  Mostofi FK, Sobin LH; World Health Organization (WHO). Histological typing of testis tumours. Geneva: WHO; 1977. International Histological Classification of Tumours, No 16.

2.  Pottern LM, Goedert JJ. Epidemiology of testicular cancer. In: Javadpour N, ed. Principles and management of testicular cancer. New York, NY: Thieme; 1986:107-119.

3.  Daniels IR, Layer GT. Testicular tumours presenting as gynaecomastia. Eur J Surg Oncol. 2003;29:437-439.

• 摘要

4.  Adami HO, Bergstrom R, Mohner M, et al. Testicular cancer in nine northern European countries. Int J Cancer. 1994;59:33-38.

• 摘要

5.  Dearnaley DP, Huddart RA, Horwich A. Managing testicular cancer. BMJ. 2001;322:1583-1588.

• 全文
• 摘要

6.  American Cancer Society. Cancer facts and figures 2005. Atlanta, GA: American Cancer Society; 2005.

• 全文

7.  Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007. CA Cancer J Clin. 2007;57:43-66.

• 全文
• 摘要

8.  Huyghe E, Matsuda T, Thonneau P. Increasing incidence of testicular cancer worldwide: a review. J Urol 2003;170:5-11.

• 摘要

9.  McGlynn KA, Devesa SS, Graubard BI, et al. Increasing incidence of testicular germ cell tumors among black men in the United States. J Clin Oncol. 2005;23:5757-5761.

• 摘要

10.  Friberg S, Mattson S. On the growth rates of human malignant tumors: implications for medical decision making. J Surg Oncol. 1997;65:284-297.

• 摘要

11.  Tyldesley S, Voduc D, McKenzie M, et al. Surveillance of stage I testicular seminoma: British Columbia Cancer Agency Experience 1992 to 2002. Urology. 2006;67:594-598.

• 摘要

12.  Ronnen EA, Kondagunta GV, Bacik J, et al. Incidence of late-relapse germ cell tumor and outcome to salvage chemotherapy. J Clin Oncol. 2005;23:6999-7004.

• 摘要

13.  Buetow SA. Epidemiology of testicular cancer. Epidemiol Rev. 1995;17:433-449.

• 摘要

14.  Sokal M, Peckham MJ, Hendry WF. Bilateral germ cell tumours of the testis. Br J Urol. 1980;52:158-162.

• 摘要

15.  Coupland CA, Chilvers CE, Davey G, et al. Risk factors for testicular germ cell tumours by histological tumour type. United Kingdom Testicular Cancer Study Group. Br J Cancer. 1999;80:1859-1863.

• 摘要

16.  Pottern LM, Brown LM, Hoover RN, et al. Testicular cancer risk among young men: role of cryptorchidism and inguinal hernia. J Natl Cancer Inst. 1985;74:377-381.

• 摘要

17.  Reuter VE. Origins and molecular biology of testicular germ cell tumors. Mod Pathol. 2005;18(Suppl 2):S51-S60.

• 摘要

18.  Richiardi L, Akre O, Montgomery SM, et al. Fecundity and twinning rates as measures of fertility before diagnosis of germ-cell testicular cancer. J Natl Cancer Inst. 2004;96:145-147.

• 全文
• 摘要

19.  Dong C, Lonnstedt I, Hemminki K Familial testicular cancer and second primary cancers in testicular cancer patients by histological type. Eur J Cancer. 2001;37:1878-1885.

• 摘要

20.  Dieckmann KP, Pichlmeier U. The prevalence of familial testicular cancer: an analysis of two patient populations and a review of the literature. Cancer. 1997;80:1954-1960.

• 摘要

21.  Fossa SD, Chen J, Schonfeld SJ, et al. Risk of contralateral testicular cancer: a population-based study of 29,515 U.S. men. J Natl Cancer Inst. 2005;97:1056-1066.

• 全文
• 摘要

22.  Ilic D, Misso ML. Screening for testicular cancer. Cochrane Database Syst Rev. 2011;(2):CD007853.

• 全文
• 摘要

23.  Strohsnitter WC, Noller KL, Hoover RN, et al. Cancer risk in men exposed in utero to diethylstilbestrol. J Natl Cancer Inst. 2001;93:545-551.

• 全文
• 摘要

24.  Jacobsen R, Bostofte E, Engholm G, et al. Risk of testicular cancer in men with abnormal semen characteristics: cohort study. BMJ. 2000;321:789-792.

• 全文
• 摘要

25.  Guo J, Pukkala E, Kyyronen P, et al. Testicular cancer, occupation and exposure to chemical agents among Finnish men in 1971-1995. Cancer Causes Control. 2005;16:97-103.

• 摘要

26.  Pukkala E, Weiderpass E. Socio-economic differences in incidence rates of cancers of the male genital organs in Finland, 1971-95. Int J Cancer. 2002;102:643-648.

• 摘要

27.  Suijkerbuijk RF, Sinke RJ, Meloni AM, et al. Overrepresentation of chromosome 12p sequences and karyotypic evolution in i(12p)-negative testicular germ-cell tumors revealed by fluorescence in situ hybridization. Cancer Genet Cytogenet. 1993;70:85-93.

• 摘要

28.  Pettersson A, Richiardi L, Nordenskjold A, et al. Age at surgery for undescended testis and risk of testicular cancer. N Engl J Med. 2007;356:1835-1841.

• 全文
• 摘要

29.  Kinkade S. Testicular cancer. Am Fam Physician. 1999;59:2539-2544,2549-2550.

• 全文
• 摘要

30.  Ye H, Ulbright TM. Difficult differential diagnoses in testicular pathology. Arch Pathol Lab Med. 2012;136:435-446.

• 摘要

31.  Dogra V, Bhatt S. Acute painful scrotum. Radiol Clin North Am. 2004;42:349-363.

• 摘要

32.  Marcell AV, Bell DL, Joffe A; Society for Adolescent Health and Medicine, SAHM Male Health Special Interest Group. The male genital examination: a position paper of the Society for Adolescent Health and Medicine. J Adolesc Health. 2012;50:424-425.

• 摘要

33.  Richie JP. Neoplasms of the testis. In: Walsh PC, Retik AB, Vaughan ED, et al., eds. Campell's urology. 7th ed. Philadelphia, PA: WB Saunders Company; 2001:2417-2418.

34.  Sturgeon CM, Duffy MJ, Stenman UH, et al. National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. Clin Chem. 2008;54:e11-e79.

• 全文
• 摘要

35.  Stenman UH, Lamerz R, Looijenga LH. Tumor markers in testicular cancers. In: The National Academy of Clinical Biochemistry. Laboratory medicine practice guidelines: use of tumor markers in testicular, prostate, colorectal, breast and ovarian cancers. 2009. http://www.aacc.org/ (last accessed 8 September 2016).

• 全文

36.  Lawton A, Mead G. Staging and prognostic factors in testicular cancer. Semin Surg Oncol. 1999;17:223-229.

• 摘要

37.  Che M, Tamboli P, Ro JY, et al. Bilateral testicular germ cell tumors: twenty-year experience at M. D. Anderson Cancer Center. Cancer. 2002;95:1228-1233.

• 摘要

38.  Association for Genitourinary Medicine (AGUM), Medical Society for the Study of Venereal Disease (MSSVD). 2002 National guideline for the management of epididymo-orchitis. London: Association for Genitourinary Medicine (AGUM), Medical Society for the Study of Venereal Disease (MSSVD); 2002.

39.  Sandlow JI, Winfield HN, Goldstein M. Surgery of the scrotum and seminal vesicles. In: Wein AJ, Kavoussi LR, Novick AC, et al, eds. Campbell-Walsh urology. 9th ed. Philadelphia, PA: WB Saunders; 2007:1105-1106.

40.  Bhatt S, Jafri SZ, Wasserman N, et al. Imaging of non-neoplastic intratesticular masses. Diagn Interv Radiol. 2011;17:52-63.

• 全文
• 摘要

41.  Association for Genitourinary Medicine (AGUM), Medical Society for the Study of Venereal Disease (MSSVD). 2002 National guidelines for the management of late syphilis. London: Association for Genitourinary Medicine (AGUM), Medical Society for the Study of Venereal Disease (MSSVD); 2002.

42.  Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th Edition of the AJCC Cancer Staging Manual and the Future of TNM. Ann Surg Oncol. 2010;17:1471-1474.

• 摘要

43.  US Preventive Services Task Force. Screening for testicular cancer: U.S. Preventive Services Task Force reaffirmation recommendation statement. Ann Intern Med. 2011;154:483-486.

• 全文
• 摘要

44.  Kondagunta GV, Bacik J, Bajorin D, et al. Etoposide and cisplatin chemotherapy for metastatic good-risk germ cell tumors. J Clin Oncol. 2005;23:9290-9294.

• 摘要

45.  Mead GM, Fossa SD, Oliver RT, et al. Randomized trials in 2466 patients with stage I seminoma: patterns of relapse and follow-up. J Natl Cancer Inst. 2011;103:241-249.

• 全文
• 摘要

46.  Fossa SD, Horwich A, Russell JM, et al. Optimal planning target volume for stage I testicular seminoma. J Clin Oncol. 1999;17:1146.

• 摘要

47.  Warde PR, Chung P, Sturgeon J, et al. Should surveillance be considered the standard of care in stage I seminoma? J Clin Oncol (Meeting Abstracts). 2005;23(suppl 16):abstr 4520.

• 全文

48.  Whipple GL, Sagerman RH, van Rooy EM. Long-term evaluation of postorchiectomy radiotherapy for stage II seminoma. Am J Clin Oncol. 1997;20:196-201.

• 摘要

49.  Oliver RT, Mead GM, Fogarty PJ, et al. Radiotherapy versus carboplatin for stage I seminoma: updated analysis of the MRC/EORTC randomized trial (ISRCTN27163214). J Clin Oncol (Meeting Abstracts). 2008;26(suppl 15):1.

• 全文

50.  Chung P, Mayhew LA, Warde P, et al. Management of stage I seminomatous testicular cancer: a systematic review. Clin Oncol (R Coll Radiol). 2010;22:6-16.

• 摘要

51.  Daugaard G, Petersen PM, Rorth M. Surveillance in stage I testicular cancer. APMIS. 2003;111:76-83.

• 摘要

52.  Brewster SF. Challenging the EAU 2009 guidelines on testis cancer: the risk-adapted management of stage I nonseminomatous germ cell tumours: surveillance yields equal results with less toxicity. Euro Urol. 2010;9:459-461.

53.  Cullen MH, Stenning SP, Parkinson MC, et al. Short-course adjuvant chemotherapy in high-risk stage I nonseminomatous germ cell tumors of the testis: a Medical Research Council report. J Clin Oncol. 1996;14:1106-1113.

• 摘要

54.  Calabrò F, Albers P, Bokemeyer C, et al. The contemporary role of chemotherapy for advanced testis cancer: a systematic review of the literature. Eur Urol. 2012;61:1212-1221.

• 摘要

55.  Einhorn LH, Williams SD, Loehrer PJ, et al. Evaluation of optimal duration of chemotherapy in favorable-prognosis disseminated germ cell tumors. J Clin Oncol. 1989;7:387-391.

• 摘要

56.  International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. J Clin Oncol. 1997;15:594-603.

• 摘要

57.  Daneshmand S, Albers P, Fosså SD, et al. Contemporary management of postchemotherapy testis cancer. Eur Urol. 2012;62:867-876.

• 摘要

58.  Loehrer PJ Sr, Gonin R, Nichols CR, et al. Vinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ cell tumor. J Clin Oncol. 1998;16:2500-2504.

• 摘要

59.  Bhatia S, Abonour R, Porcu P, et al. High-dose chemotherapy as initial salvage in patients with relapsed testicular cancer. J Clin Oncol. 2000;18:3346-3351.

• 摘要

60.  Lorch A, Kleinhans A, Kramar A, et al. Sequential versus single high-dose chemotherapy in patients with relapsed or refractory germ cell tumors: long-term results of a prospective randomized trial. J Clin Oncol. 2012;30:800-805.

• 摘要

61.  Incrocci L, Hop WC, Wijnmaalen A, et al. Treatment outcome, body image and sexual functioning after orchiectomy and radiotherapy for stage I-II testicular seminoma. Int J Radiat Oncol Biol Phys. 2002;53:1165-1173. [Erratum in: Int J Radiat Oncol Biol Phys. 2003;21:418.]

• 摘要

62.  Warszawski N, Schmucking M. Relapses in early-stage testicular seminoma: radiation therapy versus retroperitoneal lymphadenectomy. Scand J Urol Nephrol. 1997;31:355-359.

• 摘要

63.  Hermans BP, Sweeney CJ, Foster RS, et al. Risk of systemic metastases in clinical stage I nonseminoma germ cell testis tumor managed by retroperitoneal lymph node dissection. J Urol. 2000;163:1721-1724.

• 摘要

64.  Stephenson AJ, Sheinfeld J. Management of patients with low-stage nonseminomatous germ cell testicular cancer. Curr Treat Options Oncol. 2005;6:367-377.

• 摘要

65.  Kondagunta GV, Sheinfeld J, Mazumdar M, et al. Relapse-free and overall survival in patients with pathologic stage II nonseminomatous germ cell cancer treated with etoposide and cisplatin adjuvant chemotherapy. J Clin Oncol. 2004;22:464-467.

• 摘要

66.  Nichols CR, Catalano PJ, Crawford ED, et al. Randomized comparison of cisplatin and etoposide with either bleomycin or ifosfamide in treatment of advanced disseminated germ cell tumors. J Clin Oncol. 1998;16:1287-1293.

• 摘要

67.  Albers P, Siener R, Krege S, et al; German Testicular Cancer Study Group. Randomized phase III trial comparing retroperitoneal lymph node dissection with one course of bleomycin and etoposide plus cisplatin chemotherapy in the adjuvant treatment of clinical stage I nonseminomatous testicular germ cell tumors: AUO trial AH 01/94 by the German Testicular Cancer Study Group. J Clin Oncol. 2008;26:2966-2972.

• 全文
• 摘要

68.  Horwich A, Sleijfer DT, Fosså SD, et al. Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer. J Clin Oncol. 1997;15:1844-1852.

• 摘要

69.  Mazumdar M, Bajorin DF, Bacik J, et al. Predicting outcome to chemotherapy in patients with germ cell tumors: the value of the rate of decline of human chorionic gonadotrophin and alpha-fetoprotein during therapy. J Clin Oncol. 2001;19:2534-2541.

• 摘要

70.  Haugnes HS, Wethal T, Aass N, et al. Cardiovascular risk factors and morbidity in long-term survivors of testicular cancer: a 20-year follow-up study. J Clin Oncol. 2010;28:4649-4657.

• 全文
• 摘要

71.  Sprauten M, Darrah TH, Peterson DR, et al. Impact of long-term serum platinum concentrations on neuro- and ototoxicity in cisplatin-treated survivors of testicular cancer. J Clin Oncol. 2012;30:300-307.

• 摘要

72.  Abouassaly R, Fossa SD, Giwercman A, et al. Sequelae of treatment in long-term survivors of testis cancer. Eur Urol. 2011;60:516-526.

• 摘要

73.  Poli-Bigelli S, Rodrigues-Pereira J, Carides AD, et al. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Cancer. 2003;97:3090-3098.

• 摘要